Abstract
Nebivolol is a third generation beta blocker with vasodilator properties mediated by the stimulation of local nitric oxide production. Nebivolol is the most beta selective blocker available.
It is a hydrophilic drug characterized by a long half life and a trough to peak ratio of 90%. Nebivolol is very effective in the treatment of arterial hypertension and chronic heart failure.
Pharmacological properties determine its neutral or positive metabolic effects. Nebivolol can thus be used also in diabetes mellitus and metabolic syndrome patients.